Kymera Results Presentation Deck

KT-474 Concentration (ng/mL) Mean (+ SE) 20 15 10 5 C ● D1 D1-H6 ● KT-474 Plasma PK and IRAK4 Degradation in Patients Dosed for 28 Days is Comparable to HV Part C KT-474 Plasma PK n = 19 after Day 4; 2 patients discontinued treatment D4 D4-H6 D7-H6 D7 D11 D11-H6 D14 D14-H6 D21 D21-H6 D28 D28-H6 Mean Day 14 Cmax (MAD3: 100 mg QD) Mean Day 14 Ctrough (MAD3: 100 mg QD) KT-474 PK at the 75 mg QD dose (fed state) in patients is comparable to 100 mg QD (fasted state) in HV D31 KYMERA ©2022 KYMERA THERAPEUTICS, INC. 3 ng/mL threshold D35 D42 Mean Cmax and Ctrough levels at steady state in Part C are in line with MAD3 levels at Day 14 Mean half-life of 44 hours is within the range observed in MAD (34-59 hours) Percent Change from Baseline IRAK4 0 -20- -40- -60- -80 -100- PK/PD Correlation in Plasma/Monocytes (FLOW) 0 4 3 ng/mL threshold MAD PART C 8 12 16 20 24 28 32 36 40 KT-474 Ctrough/ng/mL KT-474 concentrations in plasma lead to same level of IRAK4 degradation in HV (n=48) and HS/AD (n=20) patients Concentrations above 3 ng/mL lead to same level of degradation (>80%) in HV and Patients protein] Mean (± SE) Absolute IRAK4 Levels by MS [fmol/µg IRAK4 Levels in PBMC in Patients at Day 28 (MS) 1.00- 0.75 0.50 0.25 0.00 Day 28 HS and AD Patients IRAK4 Levels at Day 28 (n=4) near LLOQ PAGE 33

View entire presentation